As the COVID-19 pandemic continues in Texas, our understanding of how best to treat patients has evolved.
That’s why the Texas Medical Association COVID-19 Task Force has updated its frequently asked questions (FAQ) on COVID-19 treatment.
The FAQ is based on guidance from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Texas Department of State Health Services (DSHS), and other public health organizations.
Among the new information in the FAQ:
- Possibility of re-infection with SARS-CoV-2 after recovery from COVID-19;
- Risk factors;
- Recommended diagnostic testing;
- Recommended clinical management and treatment for COVID-19 in outpatient and inpatient settings; and
- Investigational therapeutics, including remdesivir, hydroxychloroquine or chloroquine, and dexamethasone.
In addition, the task force has recently updated its FAQs on infection prevention and control and testing for COVID-19.
You can find these FAQs on TMA’s COVID-19 Resource Center, which is updated regularly with the latest news, resources, and government guidance on the coronavirus outbreak.
Last Updated On
June 23, 2020
Originally Published On
April 01, 2020